BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, November 11, 2025
Home » Blogs » BioWorld Perspectives » An end to Charlotte’s web?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

An end to Charlotte’s web?

May 10, 2016
By Mari Serebrov

Wilbur blogIn the annals of popular literature, TV shows and movie scripts, only a handful of pigs have achieved mega stardom: Napoleon, who took over a farm and assassinated his political rivals; Arnold, who epitomized the couch potato at Green Acres; Miss Piggy, who used her feminine wiles and street smarts to become the piglet diva of the Muppets; Babe, who used his sheep-herding skills to survive and land a starring role in a movie; and Wilbur, who had the best ad agent of them all.

While other famous pigs were almost human in their aspirations and lifestyle, Wilbur was, well, just a pig. He lived in the farmyard with the other animals. He liked dozing in the sun, rolling in the mud, getting his ears scratched. Yep, give him a pig’s life any day!

That was the catch. He wanted a pig’s life – not a pig’s death. Wilbur’s fear of his destiny is what set him apart from the other pigs in the pen. That and his friendship with Charlotte, the arachnid answer to Madison Avenue.

While Wilbur was just like any other pig, Charlotte’s marketing campaign declared that he was "SOME PIG!" And her campaign at the county fair created the buzz that gave Wilbur a perceived value beyond his weight in ham.

As a result, Wilbur’s story had a happy ending. For him. He got to live out his life surrounded by his friends. Of course, the farmer had to eat the cost of taking care of a big hog that did nothing but dozed in the sun, rolled around in the mud, begged to get his ears scratched and pigged out at the farmyard trough.

The story was a bit different for Babe, the other porcine hero who escaped the butcher knife by becoming a county fair celebrity. Unlike Wilbur whose claim to fame was all in Charlotte’s web, Babe earned his keep by developing a skill that brought true value to the farmer and the sheep he guarded.

Just as Charlotte did for Wilbur, some drug companies want to save their bacon by trying to make their run-of-the-farmyard pills look spectacular. They find a Charlotte to spin webs proclaiming the wonders of their drug to the market, hoping to make their product stand out as truly “TERRIFIC” or “RADIANT.” As the perceived value goes up, so does the price.

But with a farmyard trough that can’t keep up with the voracious appetite of too many Wilburs, the fairgoers are starting to demand real value and an end to the web spinning. Today, it’s not enough to proclaim “SOME PILL!” To keep their high prices, drugs have to rise above the pigs in the farmyard by delivering real value to more than their investors.

Sorry, Wilbur. Your days may be numbered.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Nov. 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Nov. 11, 2025.
  • Illustration of magnifying glass inspecting brain

    Anchoring, and bootstrapping, psychiatry into the precision medicine era

    BioWorld Science
    Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...
  • RNA strand

    Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal

    BioWorld
    In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's...
  • Lab mouse and test tubes

    UK launches strategy to replace animals in research as scientists voice concern

    BioWorld
    The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 million (US$98.6 million) for work to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing